Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark.
| Title: | Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. |
|---|---|
| Authors: | Hedgeman E; EpidStrategies, Rockville, MD, USA. Electronic address: ehedgeman@gmail.com.; Nørgaard M; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: mn@clin.au.dk.; Dalvi T; AstraZeneca, Gaithersburg, MD, USA. Electronic address: tapashi.dalvi@astrazeneca.com.; Pedersen L; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: lap@clin.au.dk.; Hansen HP; Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: HANHHA@rm.dk.; Walker J; AstraZeneca, Cambridge, United Kingdom. Electronic address: Jill.Walker@astrazeneca.com.; Midha A; AstraZeneca, Cambridge, United Kingdom. Electronic address: anita.midha1@astrazeneca.com.; Shire N; AstraZeneca, Gaithersburg, MD, USA. Electronic address: Norah.Shire@astrazeneca.com.; Boothman AM; AstraZeneca, Cambridge, United Kingdom. Electronic address: anne-marie.boothman@astrazeneca.com.; Fryzek JP; EpidStrategies, Rockville, MD, USA; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: jfryzek@epidstrategies.com.; Rigas J; AstraZeneca, Gaithersburg, MD, USA. Electronic address: James.Rigas@astrazeneca.com.; Mellemgaard A; Bornholms Hospital, Copenhagen, Denmark. Electronic address: a.mellemgaard@dadlnet.dk.; Rasmussen TR; Danish Lung Cancer Group, Odense, Denmark; Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, Denmark. Electronic address: torbrasm@rm.dk.; Hamilton-Dutoit S; Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: stephami@rm.dk.; Cronin-Fenton D; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: dc@clin.au.dk. |
| Source: | Cancer epidemiology [Cancer Epidemiol] 2021 Aug; Vol. 73, pp. 101976. Date of Electronic Publication: 2021 Jul 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101508793 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1877-783X (Electronic) Linking ISSN: 18777821 NLM ISO Abbreviation: Cancer Epidemiol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam : Elsevier |
| MeSH Terms: | Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/mortality ; Lung Neoplasms*/drug therapy ; Apoptosis* ; Ligands*; Biomarkers, Tumor/metabolism ; Denmark/epidemiology ; Adult ; Cohort Studies ; Humans ; Survival Analysis ; Treatment Outcome |
| Abstract: | Background: PD-L1 expression on tumor cells (TCs) or immune cells (ICs) may be used as a prognostic marker for survival in patients with NSCLC. We characterized PD-L1 expression on TCs or ICs in a patient cohort with NSCLC to determine associations between PD-L1 expression and overall survival (OS), according to EGFR and KRAS mutation status.; Methods: Danish patients aged >18 years diagnosed with NSCLC before 2014 on first- (N = 491), second- (N = 368), or third-line (N = 498) therapy were included. Data were extracted from population-based medical registries. Tumor samples from pathology archives were tested for biomarkers. High PD-L1 expression was defined as expression on ≥25 % of TCs or ICs based on first diagnostic biopsy or surgical resection. KRAS and EGFR mutation status were tested using PCR-based assays. Cox regression analysis was used to compute adjusted HRs and associated 95 % CIs.; Results: PD-L1 TC and IC ≥ 25 % were observed in 24.3 %-31.0 % and 11.7-14.7 % of patients, respectively. EGFR and KRAS mutations were detected in 4.7 %-8.8 % and 26.5 %-30.7 % of patients, respectively. PD-L1 TC ≥ 25 % was not associated with survival advantage in first- (HR = 0.96, 95 % CI: 0.75-1.22), second- (1.08, 0.81-1.42), or third-line (0.94, 0.74-1.20) therapy. PD-L1 IC ≥ 25 % was associated with survival advantage in second-line (HR = 0.56, 95 % CI: 0.36-0.86) and third-line (0.69, 0.49-0.97) but not first-line (1.00, 0.70-1.41) therapy.; Conclusion: No association was observed between PD-L1 TC ≥ 25 % and OS in any therapy line. PD-L1 IC ≥ 25 % may confer survival benefit among some patients who reach second-line therapy.; (Copyright © 2021. Published by Elsevier Ltd.) |
| Contributed Indexing: | Keywords: EGFR mutation; KRAS mutation; Non-small cell lung cancer; PD-L1 expression |
| Substance Nomenclature: | 0 (Biomarkers, Tumor); 0 (Ligands) |
| Entry Date(s): | Date Created: 20210704 Date Completed: 20210827 Latest Revision: 20210827 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.canep.2021.101976 |
| PMID: | 34217914 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't